Novartis reports positive Phase III data of Cosentyx

19th February 2018 (Last Updated February 19th, 2018 00:00)

Novartis has reported positive results from a Phase III study, which evaluated Cosentyx (secukinumab) for the treatment of patients with scalp psoriasis. 

Novartis has reported positive results from a Phase III study, which evaluated Cosentyx (secukinumab) for the treatment of patients with scalp psoriasis.

SCALP trial is a randomised, double-blind, placebo-controlled study designed to examine the efficacy and safety of Cosentyx in 102 patients with moderate-to-severe scalp psoriasis.

As part of the trial, eligible patients were equally randomised to receive either subcutaneous Cosentyx 300mg or placebo at weeks zero, one, two, three and four, then every four weeks for 12 weeks.

At the end of week 12, patients in the placebo group who did not achieve at least a 90% improvement from baseline in the psoriasis scalp severity index (PSSI) score were re-randomised to Cosentyx 300mg until the end of the SCALP trial.

The trial's primary endpoint was the proportion of patients who achieved PSSI 90 response rate at week 12, which was successfully achieved by the investigators.

"We believe that study data on specific manifestations such as scalp help doctors reach the right decisions with their patients."

The PSSI 90 response rates were achieved by a significantly higher proportion of patients receiving Cosentyx vs placebo at week 12, with further improvements found in those receiving Cosentyx up to week 24.

Safety profile of Cosentyx was also reportedly found to be in line with the known safety profile for Cosentyx.

Novartis Immunology and Dermatology Global Development unit head Eric Hughes said: “Cosentyx is backed by a large study programme including more than 10,000 patients in over 60 studies since our first Cosentyx study initiation ten years ago.

“We believe that study data on specific manifestations such as scalp help doctors reach the right decisions with their patients.”

Cosentyx is a fully human interleukin-17A (IL-17A) inhibitor approved to treat psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).